Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of UCPVax plus atezolizumab in HPV-positive cancers
2019-000881-39Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UCPVax and atezolizumab in human papillomavirus-associated cancer, head and neck cancer (HNC), Cervical Cancer (CC) and 2 more, sponsored by CHU de Besançon. Primary endpoint: Objective response rate at 4 months. Started Jul 2019; status: completed.
02
Drugs
UCPVaxatezolizumab
03
Conditions
human papillomavirus-associated cancerhead and neck cancer (HNC)Cervical Cancer (CC)Vulval carcinomaanal cancer
Beyond the preview
Go deeper on 2019-000881-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000881-39.